Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration.
机构：[1]Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China[2]The Key Laboratory of Molecular Biology, State Administration of Traditional Chinese Medicine,School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China[3]Department of Imaging Center, Nanfang hospital, Southern Medical University, Guangzhou 510515, China.[4]Department of Anesthesiology, Yue Bei People’s Hospital, Shaoguan, Guangdong Province, China[5]Traditional Chinese Medicine Integrated Hospital, Southern Medical University, Guangzhou 510315Guangdong, China
Shenling Baizhu San (SBS) is a well-known and classical Chinese medicine formula. It has been used for treatment of gastrointestinal disorders for about nine hundred years. Recent reports showed that it was effective in curing colitis and ameliorating the major manifestations of postoperational colorectal cancer (CRC). This study was to evaluate the effects of SBS on azoxymethane (AOM) and dextran sodium sulfate (DSS) induced colitis associated CRC (caCRC) and to analyze the underlying mechanism of SBS in preventing CRC.
The colon tissue of mice in different group was determined by immunohistochemistry and western blot. TGF-β1 in serum was measured by ELISA. Myeloid-derived suppressor cells (MDSCs) were identified by flow cytometry and immunohistochemistry.
The formed neoplasms phenotypically resembled human caCRC with upregulated β-catenin, p53 and proliferating cell nuclear antigen (PCNA). SBS treatment reduced the death rate of mice and decreased the incidence and multiplicity of colonic neoplasms. SBS decreased the number of MDSCs and the level of transforming growth factor β1 (TGF-β1). SBS alleviated epithelial mesenchymal transition (EMT) through downregulating N-cadherin (N-cad), Vimentin, Fibronectin, Snail, and upregulating E-cadherin (E-cad). It reduced the activation of Wnt5a and EMT induced by TGF-β1.
SBS reduced the death rate through decreasing the incidence and multiplicity of colonic tumors. SBS lowered MDSCs infiltration and inhibited TGF-β1 induced EMT to exert its anti-caCRC effects.
基金：
National Science Foundation of China (No.
81273621), Specialized Research Fund for the Doctoral Program of Higher
Education (No. 20134433110007) and Baiyun District Science and Technology
Program (No. 2012-KZ-81).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类|4 区医学
小类|3 区全科医学与补充医学
最新[2025]版：
无
第一作者：
第一作者机构：[1]Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China[2]The Key Laboratory of Molecular Biology, State Administration of Traditional Chinese Medicine,School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China[2]The Key Laboratory of Molecular Biology, State Administration of Traditional Chinese Medicine,School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China
推荐引用方式(GB/T 7714)：
Lin Xiaochang,Xu Wenjuan,Shao Meng,et al.Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration.[J].BMC complementary and alternative medicine.2015,15:126.doi:10.1186/s12906-015-0649-9.
APA：
Lin Xiaochang,Xu Wenjuan,Shao Meng,Fan Qin,Wen Ge...&Sun Xuegang.(2015).Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration..BMC complementary and alternative medicine,15,
MLA：
Lin Xiaochang,et al."Shenling Baizhu San supresses colitis associated colorectal cancer through inhibition of epithelial-mesenchymal transition and myeloid-derived suppressor infiltration.".BMC complementary and alternative medicine 15.(2015):126
